What are the differences in efficacy and safety among empagliflozin, dapagliflozin, and canagliflozin in managing type 2 diabetes?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18863003
Cited by: 0

Abstract

The efficacy and safety profiles of empagliflozin, dapagliflozin, and canagliflozin are generally similar for managing type 2 diabetes, though there are differences in cardiovascular and renal outcomes as well as side-effect profiles.

Fields of Study & Subjects

Diabetes Treatment and Management Diabetes Management and Research Heart Failure Treatment and Management

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
4 March 2026
Language
EN